Skip to main content

Prevention of Infectious Mastitis by Oral Administration of Lactobacillus salivarius PS2 During Late Pregnancy.

  • 2015-11-26
  • Clinical Infectious Diseases 62(5)
    • L. Fernández
    • Nívia Cárdenas
    • Rebeca Arroyo
    • S. Manzano
    • E. Jiménez
    • V. Martín
    • J. M. Rodríguez

Abstract

Background: Previous studies have shown that oral administration of lactobacilli can be an efficient approach to treat lactational infectious mastitis. In this trial, we have evaluated the potential of Lactobacillus salivarius PS2 to prevent this condition when orally administered during late pregnancy to women who had experienced infectious mastitis after previous pregnancies.

Methods: In this study, 108 pregnant women were randomly assigned to one of 2 groups. Those in the probiotic group (n = 55) ingested daily 9 log10 colony-forming units of L. salivarius PS2 from approximately week 30 of pregnancy until delivery, whereas those in the placebo group (n = 53) received a placebo. The occurrence of mastitis was evaluated during the first 3 months after delivery.

Results: Globally, 44 of 108 women (41%) developed mastitis; however, the percentage of women with mastitis in the probiotic group (25% [n = 14]) was significantly lower than in the control group (57% [n = 30]). When mastitis occurred, the milk bacterial counts in the probiotic group were significantly lower than those obtained in the placebo group.

Conclusions: Oral administration of L. salivarius PS2 during late pregnancy appears to be an efficient method to prevent infectious mastitis in a susceptible population.

Clinical trials registration: NCT01505361.

Keywords: Lactobacillus salivarius; mastitis; pregnancy; prevention; probiotics.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lactobacillus SalivariusReduced Incidence of Infectious MastitisBeneficial
Large
Lactobacillus SalivariusReduced Milk Bacterial Counts During MastitisBeneficial
Moderate
Lactobacillus salivarius BLIS K12Reduced Milk Bacterial CountsBeneficial
Moderate
Lactobacillus salivarius BLIS K12Reduced Occurrence of MastitisBeneficial
Moderate
Lactobacillus salivarius CRL 1328Reduced Incidence of Infectious MastitisBeneficial
Large
Lactobacillus salivarius CRL 1328Reduced Milk Bacterial Counts During MastitisBeneficial
Moderate
Lactobacillus salivarius HA-118Reduced Incidence of Infectious MastitisBeneficial
Large
Lactobacillus salivarius HA-118Reduced Milk Bacterial Counts During MastitisBeneficial
Moderate
Lactobacillus salivarius SD-5208Reduced Incidence of Infectious MastitisBeneficial
Large
Lactobacillus salivarius SD-5208Reduced Milk Bacterial Counts During MastitisBeneficial
Moderate
Lactobacillus salivarius SD-5851Reduced Incidence of Infectious MastitisBeneficial
Large
Lactobacillus salivarius SD-5851Reduced Milk Bacterial Counts During MastitisBeneficial
Moderate
Lactobacillus salivarius UALb-07Reduced Incidence of Infectious MastitisBeneficial
Large
Lactobacillus salivarius UALb-07Reduced Milk Bacterial Counts During MastitisBeneficial
Moderate
Lactobacillus salivarius UALs07Reduced Incidence of Infectious MastitisBeneficial
Large
Lactobacillus salivarius UALs07Reduced Milk Bacterial Counts During MastitisBeneficial
Moderate
Lactobacillus salivarius UCC118Reduced Incidence of Infectious MastitisBeneficial
Large
Lactobacillus salivarius UCC118Reduced Milk Bacterial Counts During MastitisBeneficial
Moderate
⬆ Back to top
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.
Receive updates about our products, services, sales, and special offers. Unsubscribe anytime. See our Privacy Policy for details on how we handle your information.

Join Our Community

Use support@pillser.com to get in touch.